Clesrovimab  (Synonyms: MK1654)

Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

MK1654

2429913-18-6

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Clesrovimab. The EC₅₀ for this effect is 4.686 ng/mL.

• [1]. Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53.  [Content Brief]

  [2]. Odumade OA, et al. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clin Infect Dis. 2022 Aug 15;75(Supplement_1):S130-S135.  [Content Brief]

  [3]. Phuah JY, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother. 2023 Dec 31;169:115851.  [Content Brief]